Annovis Promotes Cheng Fang to Chief Scientific Officer Ahead of Key Phase 3 Data
Event summary
- Cheng Fang, Ph.D., promoted to Chief Scientific Officer at Annovis Bio effective July 1, 2026.
- Fang previously served as Senior Vice President of Research and Development since joining in 2021.
- Promotion coincides with the impending top-line data readout from the Phase 3 Alzheimer’s study for buntanetap.
- Buntanetap targets neurotoxic proteins via RNA-targeting mechanism, aiming to halt neurodegeneration.
The big picture
Annovis Bio’s promotion of Cheng Fang to Chief Scientific Officer underscores the company’s focus on leveraging deep translational research expertise as it approaches critical clinical milestones. The move aligns with broader industry trends where biotech firms prioritize scientific leadership to navigate complex neurodegenerative disease therapies and regulatory hurdles. With buntanetap targeting multiple neurotoxic proteins, Annovis is positioning itself at the forefront of a potential paradigm shift in Alzheimer’s and Parkinson’s treatment.
What we're watching
- Clinical Trial Momentum
- How the Phase 3 data readout for buntanetap will shape Annovis’ regulatory pathway and investor confidence.
- Scientific Leadership Impact
- Whether Fang’s promotion strengthens Annovis’ ability to navigate complex neurodegenerative disease mechanisms.
- Regulatory Strategy
- The pace at which Annovis advances its NDA submission following the Phase 3 results.
Related topics